{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:53:37Z","timestamp":1767894817394,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,8,17]],"date-time":"2011-08-17T00:00:00Z","timestamp":1313539200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s00115-011-3360-1","type":"journal-article","created":{"date-parts":[[2011,8,17]],"date-time":"2011-08-17T12:00:05Z","timestamp":1313582405000},"page":"236-242","source":"Crossref","is-referenced-by-count":6,"title":["Therapie der Multiplen Sklerose mit Fingolimod","Fingolimod treatment for multiple sclerosis patients"],"prefix":"10.1007","volume":"83","author":[{"given":"A.","family":"Winkelmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"L\u00f6bermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.C.","family":"Reisinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.K.","family":"Zettl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,8,17]]},"reference":[{"key":"3360_CR1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00115-010-3075-8","volume":"82","author":"Aktas","year":"2011","unstructured":"Aktas O, Ingwersen J, Kieseier B et al (2011) Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system. Nervenarzt 82:215\u2013225","journal-title":"Nervenarzt"},{"key":"3360_CR2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402\u2013415","journal-title":"N Engl J Med"},{"key":"3360_CR3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ana.22426","volume":"69","author":"Cohen","year":"2011","unstructured":"Cohen JA, Chun J (2011) Mechanisms of fingolimod\u2019s efficacy and adverse effects in multiple sclerosis. Ann Neurol 69:759\u2013777","journal-title":"Ann Neurol"},{"key":"3360_CR4","unstructured":"EMA (2011) Gilenya: EPAR \u2013 Product Information. 30\/03\/2011. Online: www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002202\/WC500104528.pdf"},{"key":"3360_CR5","unstructured":"FDA (2010) Gilenya-Approved Labeling Text. 21 September 2010. Online: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022527s000lbl.pdf"},{"key":"3360_CR6","doi-asserted-by":"crossref","unstructured":"Hackett CB, Wall D, Fitzgerald SF et al (2011) Varicella zoster virus immunity in dermatological patients on systemic immunosuppressant treatment. Br J Dermatol (in press)","DOI":"10.1111\/j.1365-2133.2011.10315.x"},{"key":"3360_CR7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clim.2010.06.005","volume":"137","author":"Johnson","year":"2010","unstructured":"Johnson TA, Shames I, Keezer M et al (2010) Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients. Clin Immunol 137:15\u201320","journal-title":"Clin Immunol"},{"key":"3360_CR8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387\u2013401","journal-title":"N Engl J Med"},{"key":"3360_CR9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00115-009-2865-3","volume":"81","author":"L\u00f6bermann","year":"2010","unstructured":"L\u00f6bermann M, Winkelmann A, Reisinger EC, Zettl UK (2010) Impfen und Multiple Sklerose. Nervenarzt 81:181\u2013193","journal-title":"Nervenarzt"},{"key":"3360_CR10","unstructured":"Loebermann M, Borso D, Hilgendorf I et al (2011) Immunization in the adult immunocompromised host. Autoimmun Rev. DOI 10.1016\/j.autrev.2011.05.015 (Epub ahead of print)"},{"key":"3360_CR11","doi-asserted-by":"crossref","first-page":"A372","DOI":"10.1212\/WNL.0b013e3181cbcd48","volume":"74","author":"Mehling","year":"2010","unstructured":"Mehling M, Fritz S, Hilbert P et al (2010) Cellular and humoral influenza vaccine-specific immune responses in patients with multiple sclerosis treated with FTY720 or interferon-beta. Neurology 74:A372","journal-title":"Neurology"},{"key":"3360_CR12","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.22352","volume":"69","author":"Mehling","year":"2011","unstructured":"Mehling M, Hilbert P, Fritz S et al (2011) Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol 69:408\u2013413","journal-title":"Ann Neurol"},{"key":"3360_CR13","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1212\/WNL.0b013e31820db341","volume":"76","author":"Mehling","year":"2011","unstructured":"Mehling M, Johnson TA, Antel J et al (2011) Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 76:S20\u2013S27","journal-title":"Neurology"},{"key":"3360_CR14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jinf.2010.04.004","volume":"61","author":"Molton","year":"2010","unstructured":"Molton J, Smith C, Chaytor S et al (2010) Seroprevalence of common vaccine-preventable viral infections in HIV-positive adults. J Infect 61:73\u201380","journal-title":"J Infect"},{"key":"3360_CR15","unstructured":"Novartis (2011) Gilenya Fachinformation. M\u00e4rz 2011. Online: www.fachinfo.de\/data\/fi\/jsearch?praep"},{"key":"3360_CR16","first-page":"S135","volume":"16","author":"Schmouder","year":"2010","unstructured":"Schmouder R, Boulton C, Wang N, David O (2010) Effects of fingolimod on antibody response following steady state dosing in healthy volunteers: 4-week, randomized, placebo-controlled study. Mult Scler 16:S135","journal-title":"Mult Scler"},{"key":"3360_CR17","first-page":"353","volume":"39","author":"STIKO","year":"2005","unstructured":"STIKO (2005) Hinweise zu Impfungen f\u00fcr Patienten mit Immundefizienz. Epidemiol Bull 39:353\u2013364","journal-title":"Epidemiol Bull"},{"key":"3360_CR18","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1212\/WNL.0b013e31821043b5","volume":"76","author":"Uccelli","year":"2011","unstructured":"Uccelli A, Ginocchio F, Mancardi GL, Bassetti M (2011) Primary varicella zoster infection associated with fingolimod treatment. Neurology 76:1023\u20131024","journal-title":"Neurology"},{"key":"3360_CR19","doi-asserted-by":"crossref","unstructured":"Winkelmann A, Loebermann M, Reisinger EC et al (2011) Fingolimod treatment for MS patients \u2013 what do we do with varicella? Ann Neurol (in press)","DOI":"10.1002\/ana.22605"},{"key":"3360_CR20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0264-410X(01)00276-6","volume":"20","author":"Wutzler","year":"2001","unstructured":"Wutzler P, Farber I, Wagenpfeil S et al (2001) Seroprevalence of varicella-zoster virus in the German population. Vaccine 20:121\u2013124","journal-title":"Vaccine"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-011-3360-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-011-3360-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-011-3360-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T00:21:06Z","timestamp":1560471666000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-011-3360-1"}},"subtitle":["Infektiologische Aspekte und Hinweise zum Impfverhalten","Infectiological aspects and recommendations for vaccinations"],"short-title":[],"issued":{"date-parts":[[2011,8,17]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["3360"],"URL":"https:\/\/doi.org\/10.1007\/s00115-011-3360-1","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,17]]}}}